Caroline Gaynor

Caroline Gaynor is a Partner of Lightstone Ventures and focuses on new investments in the biopharmaceutical and medical device sectors out of the firm’s Dublin office. She currently serves as a board director for Catamaran Bio, Parvalis Therapeutics, ProVerum Medical, Carrick Therapeutics, Amber Therapeutics and Volta Medical and FIRE-1 and as board observer for Cerevance. She also previously served on the board of ALX Oncology. She is vice chair of the Irish Venture Capital Association and a member of the BioInnovate Ireland Board of advisors.

Caroline joined Lightstone Ventures in 2017, bringing 15 years’ operational experience in the pharmaceutical industry and early stage medtech companies.  Caroline spent 9 years at Bayer Healthcare, most recently serving on the board of senior management of Bayer Ltd. Ireland as head of market access, pricing and reimbursement. During her time in pharma she held a number of operational roles, predominantly focused on oncology, such as product management, strategic marketing, business development and regulatory/clinical affairs. Prior to Lightstone, and following completion of her BioInnovate fellowship in 2013, she co-led R&D on a device targeting Acute Pancreatitis and was subsequently involved in early pre-clinical, strategic clinical and commercial development at Vetex Medical. In 2002 She received her degree in Pharmacy from Trinity College Dublin and subsequently went on to receive an M.Sc in Pharmaceutical Medicine in 2010 and M.Sc in BioInnovation in 2013.